CUREator
Australia
Company overview
CUREator company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- —
- Headquarters
- Australia
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 16.8
- Investment activity
- 11 companies · latest Sep 2025
- Capital deployed
- $13M
- Preferred round
- GRANT
Valuation & funding
CUREator funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2021 | $40M | $160M | Undisclosed | ↗ |
Capital deployed
CUREator investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CeretasBrisbane, AustraliaTherapeutic ultrasound technology for neurological disease treatment
$12Mvaluation
SynaptraBIOSydney, AustraliaAI-powered drug discovery for neurodegenerative diseases
→
xCystence BioDistrict of Tuggeranong, AustraliaTherapeutics for Polycystic Kidney Disease treatment
→
Skin2NeuronSydney, AustraliaRegenerative medicine transforming hair follicles into millions of pure neurons, gene modification free
→
Sydney Neuroimaging Analysis CentreSydney, AustraliaAI-powered neuroimaging analysis for clinical trials and research
→
RedenlabMelbourne, AustraliaRedenlab’s digital speech platform supports the delivery of meaningful outcomes through the objective measurement of communication
→
DentericMelbourne, AustraliaDeveloping vaccines for treating and preventing severe periodontal disease, with the ultimate goal of improving the health of people with this disease
$36Mvaluation
Perx HealthSydney, AustraliaDisease management that is simple, exciting and rewarding Perx runs programs on behalf of hospitals, pharmaceutical companies and insurers
$7.8Mvaluation
CytophenixPerth, AustraliaRapid antimicrobial susceptibility tests delivering swift, accurate results to combat infections and antimicrobial resistance
$5.2Mvaluation
GILZRxAustraliaGILZRx is developing an anti-inflammatory therapeutic small molecule for the treatment of inflammatory and autoimmune diseases, including lupus.
$2.6Mvaluation
OccuRxMelbourne, AustraliaPrimary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis
$38Mvaluation
Talent graph
CUREator's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where CUREator has talent and traffic
In the news
Latest news about CUREator
Recent press, funding announcements, and product moves mentioning CUREator — open to read from the original sources.
Market sentiment
What the market is saying about CUREator
An AI-synthesized read of the highest-engagement posts about CUREator on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CUREator’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.